Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jacqueline Bohn"'
Publikováno v:
Obstetrics and gynecologyREFERENCE. 139(1)
Objective To evaluate the cost effectiveness of sequential medical and surgical therapy for the treatment of endometriosis-related dysmenorrhea. Methods A cost-effectiveness model was created to compare three stepwise medical and surgical treatment s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96fe0c01298d31c96b6388dc762e359
https://pubmed.ncbi.nlm.nih.gov/34623067
https://pubmed.ncbi.nlm.nih.gov/34623067
Publikováno v:
Gynecologic Oncology. 162:S8-S9
Objectives: The standard of care for patients with endometrial complex atypical hyperplasia (CAH) is a total hysterectomy. The underlying risk of finding endometrial cancer at the time of hysterectomy is as high as 43%. Both general gynecologists and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4b81d028cdd270addb4d28bd3be726e
https://doi.org/10.1016/s0090-8258(21)00664-8
https://doi.org/10.1016/s0090-8258(21)00664-8
Autor:
Jacqueline Bohn, William E. Winter, Aaron B. Caughey, Amanda S. Bruegl, Mercedes Weisenberger, Alyssa R. Hersh, Samantha Batman
Publikováno v:
Gynecologic oncology. 160(1)
Objective Uterine papillary serous carcinoma (UPSC) is a variant of endometrial cancer that is aggressive and associated with poor outcomes. We sought to evaluate the cost effectiveness of carboplatin/paclitaxel alone versus carboplatin/paclitaxel wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c9a6a7544f09f2baf91563468201d17
https://pubmed.ncbi.nlm.nih.gov/33393480
https://pubmed.ncbi.nlm.nih.gov/33393480
Autor:
Aaron B. Caughey, Elizabeth Munro, Miriam Hernandez-Zepeda, Jacqueline Bohn, Alyssa R. Hersh, Amanda S. Bruegl, Jenna M. Kahn
Publikováno v:
Gynecologic Oncology. 162:S142
Objectives: Obesity is a major public health concern and can have a negative impact on surgical outcomes. In 2018, a large, randomized control trial evaluated outcomes of minimally invasive radical hysterectomy (MIH) versus open abdominal radical hys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5acdfe41a26753334b26d1bad4e32307
https://doi.org/10.1016/s0090-8258(21)00911-2
https://doi.org/10.1016/s0090-8258(21)00911-2
Publikováno v:
American Journal of Obstetrics and Gynecology. 222:S813-S814
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::493ef2eadd1f25e0a9814c39bc11e696
https://doi.org/10.1016/j.ajog.2019.12.104
https://doi.org/10.1016/j.ajog.2019.12.104
Publikováno v:
Journal of Minimally Invasive Gynecology. 27:S43
Study Objective To evaluate the cost-effectiveness of sequential therapy for the treatment of endometriosis-related dysmenorrhea Design A cost-effectiveness model was created to compare four stepwise treatment strategies for dysmenorrhea. Probabiliti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a1704047993b1e2b4d6cab31c12a18f
https://doi.org/10.1016/j.jmig.2020.08.368
https://doi.org/10.1016/j.jmig.2020.08.368
Autor:
Jean-Christophe Hau, Alain De Pover, Dirk Erdmann, Patrick Chène, Patricia Fontana, Jacqueline Bohn, Catherine Zimmermann, Anke Blechschmidt
Publikováno v:
The Open Enzyme Inhibition Journal. 3:27-37
The insulin-like growth factor-1 receptor (IGF1R) is a drug target for oncology, and many studies are ongoing to identify compounds that inhibit its tyrosine kinase activity. IGF1R is highly homologous to the insulin receptor (IR) and IGF1R inhibitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f26296e75f431cc871a562b2aeaa2a6
https://doi.org/10.2174/1874940201003010027
https://doi.org/10.2174/1874940201003010027
Autor:
Jacqueline Bohn, Alain De Pover, Andreas Floersheimer, Patrizia Fontana, Dirk Erdmann, Bertrand Allard, Patrick Chène, Marc Gerspacher, Francesco Hofmann, Jean Christophe Hau, Thomas Radimerski, Roman Wille, Catherine Zimmermann
Publikováno v:
The Open Enzyme Inhibition Journal. 1:80-84
The Janus kinase 2 (JAK2) is a drug target in particular because a missense mutation in this gene (V617F) has been identified in various human diseases. We report here the first kinetic study of the human full-length wild type and V617F JAK2 proteins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1903216377305a842c50d32697beca01
https://doi.org/10.2174/1874940200801010080
https://doi.org/10.2174/1874940200801010080
Autor:
Pascal Furet, Jacqueline Bohn, Patrick Chène, Doriano Fabbro, Carlos Garcia-Echeverria, Jean Fuchs
Publikováno v:
Journal of Molecular Biology. 299:245-253
The hdm2 protein negatively regulates p53 tumour suppressor activity. Upon binding to p53, hdm2 stimulates p53 degradation and inhibits its transcriptional activity. Moreover, the hdm2 protein is overexpressed in various tumours inactivating p53. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcf2d3640040e9ba6edafa17db803211
https://doi.org/10.1006/jmbi.2000.3738
https://doi.org/10.1006/jmbi.2000.3738
Publikováno v:
Journal of biochemistry and molecular biology. 40(1)
Helicases are ubiquitous enzymes, which utilize the energy liberated during nucleotide triphosphate hydrolysis to separate double-stranded nucleic acids into single strands. These enzymes are very attractive targets for the development of new antibac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f51fd537405dc0034208727a3a602f
https://pubmed.ncbi.nlm.nih.gov/17244476
https://pubmed.ncbi.nlm.nih.gov/17244476